Advertisement

EJNMMI Research

, 9:42 | Cite as

Photonuclear production, chemistry, and in vitro evaluation of the theranostic radionuclide 47Sc

  • C. Shaun Loveless
  • Lauren L. Radford
  • Samuel J. Ferran
  • Stacy L. Queern
  • Matthew R. Shepherd
  • Suzanne E. LapiEmail author
Open Access
Original research
  • 68 Downloads

Abstract

Background

In molecular imaging and nuclear medicine, theranostic agents that integrate radionuclide pairs are successfully being used for individualized care, which has led to rapidly growing interest in their continued development. These compounds, which are radiolabeled with one radionuclide for imaging and a chemically identical or similar radionuclide for therapy, may improve patient-specific treatment and outcomes by matching the properties of different radionuclides with a targeting vector for a particular tumor type. One proposed theranostic radionuclide is scandium-47 (47Sc, T1/2 = 3.35 days), which can be used for targeted radiotherapy and may be paired with the positron emitting radionuclides, 43Sc (T1/2 = 3.89 h) and 44Sc (T1/2 = 3.97 h) for imaging. The aim of this study was to investigate the photonuclear production of 47Sc via the 48Ti(γ,p)47Sc reaction using an electron linear accelerator (eLINAC), separation and purification of 47Sc, the radiolabeling of somatostatin receptor-targeting peptide DOTATOC with 47Sc, and in vitro receptor-mediated binding of [47Sc]Sc-DOTATOC in AR42J somatostatin receptor subtype two (SSTR2) expressing rat pancreatic tumor cells.

Results

The rate of 47Sc production in a stack of natural titanium foils (n = 39) was 8 × 107 Bq/mA·h (n = 3). Irradiated target foils were dissolved in 2.0 M H2SO4 under reflux. After dissolution, trivalent 47Sc ions were separated from natural Ti using AG MP-50 cation exchange resin. The recovered 47Sc was then purified using CHELEX 100 ion exchange resin. The average decay-corrected two-step 47Sc recovery (n = 9) was (77 ± 7)%. A radiolabeling yield of > 99.9% of [47Sc]Sc-DOTATOC (0.384 mg in 0.3 mL) was achieved using 1.7 MBq of 47Sc. Blocking studies using Octreotide illustrated receptor-mediated uptake of [47Sc]Sc-DOTATOC in AR42J cells.

Conclusions

47Sc can be produced via the 48Ti(γ,p)47Sc reaction and separated from natural Ti targets with a yield and radiochemical purity suitable for radiolabeling of peptides for in vitro studies. The data in this work supports the potential use of eLINACs for studies of photonuclear production of medical radionuclides and the future development of high-intensity eLINAC facilities capable of producing relevant quantities of carrier-free radionuclides currently inaccessible via routine production pathways or limited due to costly enriched targets.

Keywords

47Sc Photonuclear Bremsstrahlung Titanium Accelerator eLINAC 

Abbreviations

eLINAC

Electron linear accelerator

HPGe

High purity germanium

HPLC

High-pressure liquid chromatography

PET

Positron emission tomography

ROI

Region of interest

SEM

Standard error of the mean

SSTR

Somatostatin receptor subtype 2

TLC

Thin-layer chromatography

Introduction

Theranostic applications in molecular imaging and therapy involve the use of a radionuclide or radionuclide pairs with nuclear, physical, and biological characteristics that allow tailored imaging and therapy in the same patient [1]. This personalized approach to nuclear medicine offers the possibility of matching the properties of different theranostic radionuclides with a targeting vector for distinct tumor types. Important parameters often considered when selecting suitable radionuclides include availability, chemistry, biological properties, half-life, and decay properties. Therefore, the development of new production routes for hard to obtain theranostic radionuclides can provide innovative diagnostic and therapeutic agents for use in personalized nuclear medicine [1, 2, 3].

Recently, the development of receptor-targeted radionuclide therapies has highlighted the need for the rapid and complete assessment of their pharmacokinetics [4, 5, 6]. To address this need, imaging with a chemically identical diagnostic (labeled with a radionuclide of the same element) affords the truest picture of in vivo distribution for the therapeutic agent [7]. Therefore, the development of matched radionuclide pairs for use in receptor-targeted therapies and imaging is an emerging area of research. Unfortunately, the limited availability of a number of the most promising matched-pair theranostic radionuclides has hindered pre-clinical research and translation of new therapeutic agents to the clinic [7].

The theranostic radionuclide scandium-47 (47Sc, T1/2 = 3.35 days, Eβavg = 162 keV, Eγ = 159 keV, I = 68.4%) has a half-life of 3.35 days and is compatible with the biological half-life of antibodies or peptide-based radiopharmaceuticals [8, 9]. It decays by β emission with an average β energy of 162 keV, followed by prompt emission of a 159 keV gamma ray (68.4%) to stable 47Ti [10]. Further, 43Sc (T1/2 = 3.89 h, Eβ+avg = 476 keV, I = 88.1%) and 44Sc (T1/2 = 3.97 h, Eβ+avg = 632 keV, I = 94.3%) have been proposed as diagnostic radionuclides for positron emission tomography (PET) imaging [11].

Reactor production of 47Sc has been investigated using neutron capture on enriched titanium via the 47Ti(n,p)47Sc reaction (En > 1 MeV) or neutron capture on enriched calcium 46Ca(n,γ)47Ca (En = 0.025 eV), resulting in 47Ca (T1/2 = 4.54 days), which may be used for a 47Ca-47Sc generator system [12, 13]. One challenge facing development of a 47Ca-47Sc generator is the natural abundance of 46Ca (0.004%). Due to this abundance, it is only available at enrichment levels up to 30% [14]. Accelerator production and measurement of cross sections for the production of 47Sc have been investigated using medium to high energy protons (17 < Ep < 150 MeV) via the natTi(p,2p)47Sc, 48Ti(p,2p)47Sc, 51V(p,3pn)47Sc, and natCa(p,2n)47Sc reactions [1, 14, 15]. Cyclotron production via the above methods resulted in co-production of 46Sc (T1/2 = 83.79 days) and 48Sc (T1/2 = 43.67 h), decreasing the radionuclidic purity of 47Sc. Production with spallation neutrons was also investigated via the 47Ti(n,p)47Sc, natV(n,x)47Sc, and natTi(n,x)47Sc reactions [16]. Based on these data, production routes that afford radionuclidic purity suitable for clinical application require costly enriched targets or access to nuclear reactors with significant high energy neutron flux (En > 1 MeV). Therefore, the poor availability of 47Sc, due to the above requirements, has hampered preclinical investigation and clinical application of the 47Sc/43,44Sc theranostic matched-pair.

In an effort to address the above challenges, recent work has investigated the use of high-intensity electron linear accelerators (eLINACs) with 20–55 MeV electron beams to produce 47Sc via photonuclear reactions on titanium nuclei [17, 18]. The electrons accelerated by these machines emit bremsstrahlung radiation as they pass through matter, resulting in a spectrum of photon energies ranging from zero to the electron energy with a flux that is inversely proportional to the energy of the radiated photon. A small fraction of the bremsstrahlung photons are energetic enough to induce photonuclear reactions such as (γ,n) and (γ,p) for radionuclide production [10, 19]. The flux of bremsstrahlung photons can be enhanced with the use of a radiator or “converter” made from a high Z material, like tungsten. Use of a radiator does not significantly alter the energy distribution of radiated photons, but it enhances the number of radiated photons and hence increases the number that are energetic enough to induce photonuclear reactions. Rotsch et al. (2018) used natTiO2 targets to demonstrate a 47Sc production rate at 35 MeV and 40 MeV of 4.25 MBq/g·kW·h and 6.92 MBq/g·kW·h, respectively, using bremsstrahlung photons [20]. Belyshev et al. (2015) showed that the integrated cross section of the natTi(γ,p)47Sc reaction, using thin titanium foils of natural isotopic composition, was 110 ± 19 mb using a 55 MeV electron beam [18]. T. R. Sherwood and W. E. Turchinetz (1962) measured the cumulative cross section of the natTi(γ,p)47Sc reaction, yielding a peak cross section of approximately 28 mb at 23 MeV and integrated cross section of 217 ± 32 MeV·mb [21] (Fig. 1).
Fig. 1

The photonuclear cross section for the sum of the natTi(γ,p)47Sc and natTi(γ,np)47Sc nuclear reaction as a function of photon energy

A high-intensity eLINAC facility capable of photonuclear radionuclide production has many advantages in contrast to reactor or other accelerator facilities. These advantages include reduced volume of radioactive waste, low cost and operation expense, and fewer nuclear reaction channels, leading to potentially higher radiochemical purity of the final product. Previous work on photonuclear production of radionuclides using bremsstrahlung radiation has included 47Sc, 99Mo for 99Mo-99mTc generators, 67Cu for the 67Cu/64Cu theranostic matched-pair, 225Ac for targeted alpha therapy, and 195mPt as a theranostic radionuclide [17, 19, 22, 23, 24]. Therefore, a number of long-lived theranostic radionuclides or radionuclide pairs, including 47Sc, that suffer from lack of availability may be produced by photonuclear reactions at eLINAC facilities.

In this work, the photonuclear production of carrier-free 47Sc via the natTi(γ,p)47Sc reaction using bremsstrahlung radiation generated by an electron beam (22 MeV Varian CLINAC) was investigated. To isolate the produced 47Sc from natTi target material, a separation method using AG MP-50 cation exchange resin was developed. Following separation, the 47Sc was further purified using CHELEX 100 chelating resin. The purified 47Sc was used to radiolabel 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-DPhe-c (Cys-Tyr-DTrp-Lys-Thr-Cys)-Thr-ol (DOTATOC) and the in vitro binding of [47Sc]Sc-DOTATOC was then established in somatostatin receptor subtype 2 (SSTR2)-expressing AR42J cells. These results show that future photonuclear production of 47Sc at a high-intensity eLINAC facility could represent a production route capable of producing quantities needed for pre-clinical research and translation to the clinic of this important theranostic radionuclide.

Materials and methods

General materials

All chemicals were analytical or trace metals grade and used as received unless otherwise noted. Milli-Q deionized 18.2 MΩ cm water (Milli-Q System; Millipore, Billerica, MA, USA) was used unless otherwise specified. Ammonium acetate (NH4CH3CO2, 99.999%), sodium hydroxide (NaOH, pellets, 99.995%), hydrogen peroxide (H2O2, TraceSELECT® Ultra ≥ 30%), hydrochloric acid (HCl, 37% wt. in water, 99.999%), nitric acid (HNO3, 70% wt. in water, 99.999%), and sulfuric acid (H2SO4, 95–98% wt. in water, 99.999%) were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). Chelex® 100 chelating resin (100–200 mesh, Na+ form) and AG MP-50 cation exchange resin (100–200 mesh, H+ form) were purchased from Bio-Rad (Hercules, California, USA). 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-DPhe-c (Cys-Tyr-DTrp-Lys-Thr-Cys)-Thr-ol (DOTATOC) and l-Cysteinamide, d-phenylalanyl-l-cysteinyl-l-phenylalanyl-d-tryptophyl-l-lysyl-l-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2 → 7)-disulfide (Octreotide) were purchased from Bachem Americas, Inc. (Torrance, CA, USA). Type 4 N high-purity, 0.127-mm-thick, natural titanium foil was purchased from ESPI Metals (Ashland, OR, USA). Scandium (III) nitrate hydrate (Sc (NO3)3, FW: 240.97 g/mol, 99.9%) was purchased from Alfa Aesar (Heysharn, Lancashire, UK). Stock solutions of 0.25 and 1.0 M ammonium acetate buffer, pH adjusted to 4.7, were purified with columns containing Chelex® 100 resin prior to use. All glassware was acid washed in a 50% HNO3 bath overnight at room temperature.

Instrumentation

A modified Varian CLINAC (2100, Palo Alto, CA, USA) was used for all irradiations. The CLINAC was described in previous work by Queern et al. (2018) [25]. Similar to previous studies, a thin high Z material (tungsten) placed immediately upstream of the Ti target was used to enhance bremsstrahlung radiation. The average electron beam current was calibrated using an open-air AC current transformer fabricated by Bergoz Instrumentation (Saint Genis Pouilly, France). For calibration measurements, the transformer was mounted in the same location as the target holder. An electron beam energy of 22 MeV, the top setting with this CLINAC, was selected to maximize the photon flux in the region most likely to contain the highest photonuclear cross section for natTi(γ,p)47Sc.

Photonuclear production

The radionuclide 47Sc was produced via the 48Ti(γ,p)47Sc nuclear reaction by irradiation of a natTi target foil stack (39 foils, 2.0 × 2.0 × 0.135 mm) using bremsstrahlung radiation generated by impinging 22 MeV electrons onto a 0.762-mm-thick tungsten radiator.

Target dissolution

For each target foil, the region where the beam struck the foils was determined by imaging select foils for several hours with Gafchromic EBT3 radiographic film (Bridgewater, NJ, USA). The exposed films were used to create templates, which allowed for mechanical removal of activated Ti. The activated Ti was extracted from the target foils as discs using a portable lever-operated hole punch with a 3–4-mm punch (Douglasville, GA, USA). Activated discs were split into three sets and each set was treated similarly. Briefly, target foils were placed in a 50 mL round bottom flask along with 20 mL of 2.0 M H2SO4. The flask was fitted with a reflux condenser, and the apparatus was heated at 350 °C for 4 h using a sand filled mantle heater. During heating, the colorless solution became deep purple and remained clear. After heating, 1.16 mL of 30% H2O2 was added, resulting in a prompt color change from purple to intense orange. The solution was quantitatively transferred to a 100 mL beaker, whereupon 59 mL of water was added to adjust the H2SO4 molarity to 0.5 M.

Resin conditioning

Prior to use, AG MP-50 and Chelex-100 resin were treated to remove contaminants. Briefly, 50 g of AG MP-50 resin was transferred to a clean 500 mL glass media bottle. First, the resin was mixed with 20 mL of 5 M HNO3. After settling, the supernatant was decanted to remove fine resin particles and contaminants. This was repeated twice. Next, the resin was mixed with 20 mL of water. After settling, the supernatant was decanted. This was repeated until the water, after mixing, had a pH of 7. The above process was then repeated using 2 M HCl. Finally, the treated resin was stored under water until use.

Separation method

A separation method previously described by Kolsky et al. was adapted for this work [26]. A glass column (0.5 × 20 cm) was slurry packed with treated AG MP-50 cation exchange resin to a wet bed height of 2.5 cm. A glass wool plug was placed atop the resin bed. The resin was equilibrated by passing 15 mL of 0.5 M H2SO4 containing 2% H2O2 through the column at a flow rate of 1.5 mL/min. The digested target, containing 47Sc (in approximately 80 mL of 0.5 M H2SO4), was loaded onto the column at a flow rate of 1.5 mL/min. Adsorbed Ti was eluted with 40 mL of 2% H2O2 in 2.0 M H2SO4 at a flow rate of 1.5 mL/min. The resin was equilibrated with 10 mL of water and the adsorbed 47Sc was eluted with 20 mL of 1 M ammonium acetate buffer (pH 4–5). This eluate, containing 47Sc, was loaded onto a column (0.5 × 20 cm) containing Chelex® 100 chelating resin packed and prepared under conditions as described above. Adsorbed 47Sc was rinsed with 20 mL of water and eluted in 5.0 mL of 12.1 M HCl. After elution, the eluate was evaporated to a wet salt by gentle heating under nitrogen gas flow. This residue was dissolved in 1 mL of water and evaporated to dryness. This process was completed twice, resulting in a final product pH of 7. After the final evaporation the residue was dissolved in 400 μL of 0.25 M ammonium acetate (pH 4) which was used as the 47Sc solution for subsequent radiolabeling reactions. A typical separation and purification required 4 h.

Elemental analysis

Fractions preserved from separations in this work were analyzed via inductively coupled plasma mass spectrometry (ICP-MS) to determine the concentration of elements present. Multi-element standards in 2% HNO3 at 1, 50, 100, 250, 500, 750, and 1000 mg/L were used for instrument calibration. For each collected fraction, an aliquot was diluted in 2% HNO3 and analyzed on an Agilent Technologies 7800 ICP-MS (Santa Clara, CA, USA) to determine the presence of transition metals. Agilent software, ICP-MS MassHunter v4.3, was used for data acquisition and analysis.

γ-ray spectroscopy

Samples containing radionuclides in this work were characterized and quantified by γ-ray spectroscopy using a Canberra GC2018 high-purity germanium (HPGe) detector with a relative efficiency of 24.5% (Meriden, CT, USA) connected to a Canberra DSA-100 multichannel analyzer (Meriden, CT, USA). Canberra Genie 2000 software was used for all data acquisition and analysis (Meriden, CT, USA). An energy and efficiency calibration was performed using a mixed nuclide source in a sealed 1.5 mL microcentrifuge vial prepared by Eckert & Ziegler Analytics (Atlanta, GA, USA). Efficiency-calibration spectra with a minimum photopeak area of 2 × 105 counts were collected and fit to a fourth-order polynomial to determine the detector efficiency [27]. For all measurements, aliquots of sample material were transferred to a 1.5 mL vial, diluted to 1 mL, and suspended in a fixed acrylic holder at a distance of 5 mm from the HPGe detector. This geometry was maintained for all samples. The activity of characterized radioisotopes was determined based on the net peak area (NA) in each photopeak [28]. For each photopeak, the activity (A0) at the beginning of the decay-counting measurement was determined according to the following equation:
$$ {A}_0=\frac{\uplambda {N}_{\mathrm{A}}}{I_{\upgamma}\upvarepsilon \left(1-\mathrm{DT}\right)\left(1-{\mathrm{e}}^{-\uplambda {t}_{\mathrm{R}}}\right)} $$
where λ is the decay constant of the radioisotope, Iγ is the branching ratio of the γ-ray, ε is the energy-dependent photopeak efficiency of the detector, DT is average dead time during the measurement, and tR is the real time of measurement. For all measurements, the average dead time was less than 5%.

Radiosynthesis of [47Sc]Sc-DOTATOC

As described by Pruszynski et al., radiolabeling of DOTATOC (1421.60 g/mol) with 47Sc was conducted in pH 4–5 0.25 M ammonium acetate buffer [29]. In brief, 60 μL of a 6.4 μg/μL aqueous DOTATOC stock solution was added to 40 μL of 0.25 M ammonium acetate buffer in a 1.5 mL centrifuge vial. To this vial, 1.7 MBq of 47Sc dissolved in 200 μL of 0.25 M ammonium acetate was added. The reaction pH and final concentration of DOTATOC (270 nmol in 300 μL) was pH 4–5 and 0.9 mM, respectively. The reaction mixture was heated for 30 min at 95 °C using an Eppendorf Thermomixer® C fitted with a 1.5 mL heating block at 800 rpm.

[47Sc]Sc-DOTATOC characterization

Radiochemical analyses were performed using thin-layer chromatography (TLC) and high-performance liquid chromatography (HPLC). TLC analyses were performed using Agilent Technologies instant TLC-SA (iTLC) chromatography paper (Santa Clara, CA, USA) developed using a 1:1 mixture of 1.0 M ammonium acetate and methanol. TLC plates were read using an Eckert & Ziegler AR-2000 radioTLC system (Hopkington, MA, USA) and Eckert & Ziegler Winscan 3.0 software (Hopkington, MA, USA) was used to define regions of interest (ROI) and integrate peaks. HPLC analyses were performed on an Agilent Technologies HPLC (Infinity 1260, Santa Clara, CA, USA) equipped with a multi-wavelength diode-array detector followed by an in-line LabLogic detector (Flow-RAM Galbi NaI, Brandon, FL, USA) using a Thermo Scientific C18 analytical column (BetaBasic, 150 mm × 4.6 mm × 5 μm, 150 A, Waltham, MA, USA). LabLogic Laura™ radiochromatography software was used for HPLC data collection and analysis. Before any measurement by HPLC, solvents (HPLC grade) were degassed and water used for HPLC mobile phase was passed through a 0.22 μm filter. The HPLC method involved use of two solvents (A & B). Solvent A was acetonitrile (ACN) with 0.1% trifluoroacetic acid (TFA) and Solvent B was water with 0.1% TFA. The gradient elution began at 5%(A):95%(B) and changed linearly to 80%(A):20%(B) over 20 min at 1.0 mL/min.

Cell culture

All cell culture materials were purchased from Fisher Scientific unless otherwise noted. The SSTR2-positive rat pancreatic cancer cell line AR42J (ATCC, Manassas, VA, USA) was cultured in Gibco™ IMDM media supplemented with 10% fetal bovine serum (FBS) and 0.1% gentamicin. Cells were incubated at 37 °C in a 5% CO2 atmosphere and were harvested using 0.05% trypsin-EDTA. Cells were washed once with supplemented IMDM prior to use. Cells were counted with a Nexcelom (Lawrence, MA, USA) auto T4 bright field cell counter.

Competitive binding assay

AR42J cells were seeded into two 24-well plates (8 wells per plate) in 1 mL medium (1 × 105 cells/well) and incubated overnight. After incubation, media was discarded, and 1 mL of 75 kBq [47Sc]Sc-DOTATOC (12 μM) in IMDM media was transferred into each non-blocking well (4 wells/plate). For the blocking study, 1 mL of 75 kBq [47Sc]Sc-DOTATOC containing 40 μM Octreotide was added into each blocking well (4 wells/plate). Additional 1 mL aliquots of the blocking and non-blocking solutions were transferred into empty wells on each plate as a reference. One milliliter of each solution, blocking and non-blocking, was transferred to separate 1.5 mL centrifuge tubes and used as reference standards (47Sc/1 mL dose) to determine total activity added to each well. Subsequently, the two 24-well plates were incubated at 37 °C for 2 h (first plate) or 4 h (second plate). At each time point, cells were washed three times with PBS, lysed with 1.0 M NaOH, and transferred into 1.5 mL centrifuge tubes. All centrifuge tubes were counted in a HIDEX 300 SL automatic γ-counter using a 3″ NaI crystal (Turku, Finland). Data is expressed as percentage of added dose bound (% Bound) with the standard error of the mean (SEM). A one-way ANOVA test was applied to each set of data (blocking and non-blocking) at 2 h and 4 h to determine P values and difference between each observed mean.

Results

47Sc production and separation

An average 47Sc yield (n = 3) of 8 × 107 Bq/mA h was obtained using a 22 MeV electron beam with an average beam current of 1.5 μA (Table 1).
Table 1

The parameters for each irradiation are shown

Run

EOB

Time (min)

Average current (μA)

Radiator THK (mm)

Titanium Foils (no.)

1

03/29/2017 17:03:00

630

2.5

0.762

39

2

05/07/2017 11:35:00

680

2.5

0.762

40

3

10/06/2017 20:51:00

840

2.5

0.762

39

Using radiographic film, the region of produced 47Sc was mapped in select Ti foils. The beam strike, imaged on the film, of the entry and exit foil had an average diameter of 3 and 4 mm, respectively. Select foils were characterized and the presence of 46Sc (T1/2 = 83.79 days, 889.3 keV), 47Sc, and 48Sc (T1/2 = 1.82 days, 983.5, 1037.5, and 1312.1 keV) were confirmed by gamma ray analysis using characteristic gamma rays. The end-of-bombardment (EOB) radioisotopic purities of 47Sc, 46Sc, and 48Sc were determined by gamma ray analysis. The average EOB radioisotopic purity (n = 9) was (90.0 ± 0.1)% 47Sc, (1.2 ± 0.1)% 46Sc, and (8.3 ± 0.1)% 48Sc. Figure 2 shows the radioactive decay of 46,47,48Sc and 47Sc radioisotopic purity as a function of time for irradiation 3.
Fig. 2

(Left axis) The radioactive decay of 46,47,48Sc and (right axis) 47Sc radioisotopic purity produced during the third irradiation modeled over 10 days

The maximum radioisotopic purity was reached at approximately 5.85 days post-EOB (Fig. 2). Templates were fashioned using the exposed films and the region containing the greatest concentration of 47Sc was mechanically extracted from each natTi target foil. The average extraction efficiency (n = 3) was (91 ± 8)% (Fig. 3).
Fig. 3

The average extraction efficiency (n = 3) expressed as the ratio of radioactivity measured in the extracted Ti disc versus the irradiated Ti foil. The interpolated average efficiency through the target foil stack (red trace). The beam was first incident upon target foil 1

For each irradiation, the extracted discs were split into three groups (A, B, and C) and dissolved in 2 M H2SO4 under reflux conditions. After dissolution, the solution was cooled to room temperature. The solution was clear and purple. A 1 mL aliquot was removed from each group and analyzed with an HPGe detector to measure the activity associated with each radionuclide. Table 2 shows the average decay-corrected EOB 46,47,48Sc radioactivity for each irradiation (sum of A, B, and C activities).
Table 2

The average (n = 3, 1σ) 46,47,48Sc radioactivity measured in natTi discs processed in this work

Run

46Sc(kBq)

47Sc(kBq)

48Sc(kBq)

1

26 (1)

2178 (7)

229 (1)

2

25 (1)

2111 (124)

210 (17)

3

32 (1)

2420 (138)

222 (14)

In order to control Ti speciation, the digestion solution was adjusted to contain 2% of 30% H2O2 dissolved in 0.5 M H2SO4. Upon addition of hydrogen peroxide, the solution rapidly changed color to an intense orange but remained clear. In previous work, Muller and Schwarzenbach characterized the orange peroxytitanium (IV) species in solutions below pH 1, in general form, as Ti(O2)(OH)n-2(4-n)+; however, the number of hydroxyl groups has not been shown conclusively [30]. The 46,47,48Sc and peroxytitanium species mixture was directly loaded onto a column containing the treated AG MP-50 resin.

For the final optimized separation and purification (run 3), an aliquot was taken at each point in the separation and analyzed by HPGe and ICP-MS. Due to weak peroxytitanium affinity for AG MP-50 resin at low H2SO4 concentration, the absorbed natTi was recovered in the flow-through and 1 M H2SO4 eluate. The recovery (n = 3) of bulk natTi target material was quantitative as measured by ICP-MS. After the first eluent, the AG MP-50 resin was rinsed with 10 mL of water to clear hydrogen peroxide from the column. The strongly adsorbed 46,47,48Sc was then recovered in 20 mL 1 M ammonium acetate (pH 4.7). The average decay-corrected radioscandium recovery (n = 3, 1σ) was (92.2 ± 4.7)%. The concentration of metal contaminants, including Cr, Cu, Fe, Ni, and Zn, were measured in the 20 mL of the 1 M ammonium acetate eluate. The average concentration (n = 3, 1σ) of each trace metal contaminant was 191 ± 15 μg/L (Cr), 188 ± 36 μg/L (Cu), 414 ± 89 μg/L (Fe), 100 ± 30 μg/L (Ni), and 620 ± 296 μg/L (Zn) in 20 mL after this first column. A second column using CHELEX 100 was used to further purify the 46,47,48Sc solution. The 46,47,48Sc in ammonium acetate (pH 4.7) was directly loaded onto a column containing CHELEX 100 resin whereupon the 46,47,48Sc was strongly adsorbed. After rinsing with water, 46,47,48Sc was stripped from the column in 5 mL of 12.1 M HCl with an average (n = 3, 1σ) decay-corrected recovery of (91 ± 3)%. The total decay-corrected average (n = 3, 1σ) recovery was (83 ± 3)%. Similar to the above analysis, metal contaminants with a concentration > 1 μg/L were measured in the 5 mL of 12.1 M HCl eluate. The average concentration (n = 3, 1σ) of Cr, Cu, Fe, Ni, and Zn was 127 ± 6 μg/L (Cr), 169 ± 34 μg/L (Cu), 357 ± 154 μg/L (Fe), 107 ± 33 μg/L (Ni), and 189 ± 25 μg/L (Zn) in 5 mL. These data are shown in Table 3.
Table 3

The average mass (n = 3, 1σ) of contaminant metals measured in the digestant and the eluate recovered from the AG MP-50 and CHELEX 100 resin

Sample

Cr

Cu

Fe

Ni

Zn

Digestant mass (μg)

552 (30)

493 (72)

946 (35)

206 (24)

908 (620)

Post AG MP-50 (μg)

3.9 (0.3)

3.8 (0.7)

8.4 (1.8)

2.0 (0.6)

13 (6)

Post CHELEX 100 (μg)

0.6 (0.2)

0.8 (0.2)

1.8 (0.8)

0.5 (0.2)

1.9 (0.1)

The overall reduction in Cr, Cu, Fe, Ni, and Zn after separation and purification was 99.9%, 99.8%, 99.8%, 99.8%, and 99.9%, respectively.

For the final irradiation (run 3), the 12.1 M HCl eluates containing 46,47,48Sc(III) from groups A, B, and C were combined and evaporated to a wet residue under nitrogen gas with gentle heating (95 °C). The residue was dissolved in 1 mL of water and evaporated. This process was repeated twice more. After the final evaporation was conducted, the residue was dissolved in 255 μL of 0.25 M ammonium acetate (pH 4) after which a 10 μL aliquot was taken and analyzed. Figure 4 shows the characterized HPGe spectra of the final product.
Fig. 4

HPGe spectra of the purified radiolabeling solution. The photopeaks attributed to 46,47,48Sc have been characterized and labeled. The sum peak due to the intense 47Sc photopeak at 159 keV has been noted

This solution contained a 47Sc concentration of 8.5 ± 0.4 kBq/μL. The average concentration of trace metal contaminants in 255 μL of solution were 0.8 ± 0.1 mg/L (Cr), 0.8 ± 0.1 mg/L (Cu), 1.6 ± 0.1 mg/L (Fe), 1.8 ± 0.1 mg/L (Ni), and 6.0 ± 0.3 mg/L (Zn).

Radiosynthesis of [47Sc]Sc-DOTATOC

To radiolabel DOTATOC, 200 μL of 0.25 M ammonium acetate (pH 4.7) containing 1.7 MBq of 47Sc was added to 100 μL of 0.1 M ammonium acetate (pH 4) containing 0.384 mg of DOTATOC (270 nmol). The final concentration of DOTATOC was 0.9 mM with a molar activity of 6.3 kBq/nmol. The mixture was vortexed and incubated at 95 °C for 30 min.

For TLC analyses, in a 1:1 mixture of 1.0 M ammonium acetate and methanol, free 47Sc remained at the origin (Rf = 0). The TLC analysis of a 1 μL aliquot from the [47Sc]Sc-DOTATOC solution showed a single peak with an Rf value of 0.8. For HPLC analyses, the retention times of free 47Sc and DOTATOC were 1.9 min and 8.8 min, respectively. The HPLC analysis of the [47Sc]Sc-DOTATOC solution diluted with 0.25 M ammonium acetate showed a peak in the radio and UV/Vis (λ = 280 nm) spectra at 8.5 min and 8.8 min, respectively. These analyses showed the radiochemical yield was > 99.9% and thus the compound was used without further purification. The HPLC and TLC chromatograms of the [47Sc]Sc-DOTATOC solution are shown in the supplemental data (Additional file 1: Figure S1).

Competitive cell binding assay

Binding of [47Sc]Sc-DOTATOC in AR42J cells was determined in vitro at 2 and 4 h. To determine if uptake of [47Sc]Sc-DOTATOC was receptor-mediated, the ligand Octreotide was used as a blocking agent due to its known affinity for SSTR2 [31, 32]. At both 2 and 4 h (n = 4), the percentage of [47Sc]Sc-DOTATOC bound to cells was significantly decreased (p < 0.0001 and p = 0.0075) in cells that were co-incubated with Octreotide (Fig. 5).
Fig. 5

The percentage of receptor bound or internalized [47Sc]Sc-DOTATOC incubated with AR42J cells is shown on the ordinate axis at 2 and 4 h (n = 4, 1σ, SEM). Co-incubation with SSTR blocking agent Octreotide significantly decreased cell uptake

The maximum mean uptake and standard error of [47Sc]Sc-DOTATOC was achieved by 2 h (0.31 ± 0.02)%, as uptake at 4 h (0.32 ± 0.02)% was not significantly increased.

Discussion

The multiple irradiations conducted with the modified Varian CLINAC allowed for measurements of the target foil activities and beam dispersion throughout a natTi target foil stack. The diameter of the activated region increased from 3 to 4 mm throughout 39 natTi foils. For each foil, the region containing 47Sc was mechanically extracted, reducing the bulk quantity of Ti involved in the separation. While this method and the use of natural titanium metal was suitable for this work, future studies that seek to optimize 47Sc yield will require enriched titanium (IV) oxide (48Ti) targets, well-defined target geometry, target cooling, and optimized target mass due to the strong dependence between yield and the target nuclei population. Further, the use of an oxide target with a profile commensurate to the bremsstrahlung beam diameter will not require mechanical extraction to reduce unirradiated target material or high temperature methods for the reductive synthesis of Ti (0), required to recover target material after an aqueous chemical separation. Importantly, as the target mass increases, the selected separation method must be able to sequester gram quantities of target material, which must be recovered and recycled, for iterative irradiations. As future work continues on developing photonuclear production of 47Sc, these parameters should be optimized for high-intensity electron beams as they will have a direct impact on recovery and purity of the chemically isolated 47Sc.

A number of scandium radionuclides may be co-produced when using a natTi target, including 44Sc, 46Sc, 48Sc, and 49Sc. Similar to the photonuclear work previously reported by Mamtimin et al., 46Sc (T1/2 = 83.79 days) and 48Sc (T1/2 = 43.7 h) were experimentally observed in the Ti foils; however, 44Sc and 49Sc were not observed due to their short half-lives and maximum bremsstrahlung photon energy used in this work [10]. The co-production of 46Sc presents the most significant challenge to using natTi as a target material since the 47Sc radionuclidic purity decreases over time due to the longer half-life of 46Sc. The two contaminant radionuclides can, in principle, be produced via the 48Ti(γ,np)46Sc, 47Ti(γ,p)46Sc, 50Ti(γ,np)48Sc, and 49Ti(γ,p)48Sc reactions and have threshold energies of 22.1 MeV, 10.5 MeV, 22.3 MeV, and 11.3 MeV, respectively.

In the work by Mamtimin, using a 22 MeV electron beam, the EOB ratio of 46,47,48Sc activities were 0.03, 0.82, and 0.14, respectively [10]. In the work by Rotsch et al., using a 35 MeV electron beam and capturing a larger portion of the natTi(γ,p)47Sc cross section (Fig. 1), the ratio of 46,47,48Sc EOB activities produced were 0.01, 0.90, and 0.09 [20]. The ratio of 46,47,48Sc EOB activities in this work using a 22 MeV electron beam were 0.01, 0.90, and 0.09. For each study, natTi target material was used and the irradiation times were less than one half-life of the three radionuclides. These studies show that the shape of the excitation function for each radionuclide was similar, resulting in comparable radionuclidic purity at EOB even at different electron beam energies. Furthermore, when using a 22 MeV electron beam in our work, less than the threshold energies of the (γ,np) channels, no improvement in 47Sc radionuclidic purity was observed when compared to the work by Mamtimin and Rotsch, suggesting the (γ,p) reactions on 47Ti and 49Ti are the dominant sources of Sc impurities.

The 47Sc EOB radionuclidic purity was impacted by co-production of 46Sc and 48Sc for each study when using natTi target material. Thus, the best case scenario for limiting co-production of contaminants, 46Sc and 48Sc, involves the use of enriched 48Ti target material, available commercially at enrichment levels up to 99.6% [33]. Favorably, the abundant 48Ti (73.8%) may be purchased commercially at a relatively low cost (2–3$/mg) [33].

The extracted Ti foils were acid digested and a separation method using AG MP-50 cation exchange resin and CHELEX 100 resin was used to isolate the 47Sc. This separation system was selected based on previously published work using both resins [26, 34]. Initial elemental analysis of fractions preserved during separation with AG MP-50 showed varying levels of trace metal contamination due to Cr, Cu, Fe, Ni, and Zn. To reduce the concentration of these cations, which may compete with radioscandium for DOTA binding or cause transmetallation of the radioscandium-DOTA complex, a second separation step was performed to further purify the isolated 47Sc [35]. For this two-step method, the overall recovery of 47Sc for the separation and purification of was (77 ± 7)%. The observed losses during radiochemical separation were due to material transfer and loss to both the AG MP-50 and CHELEX 100 resins. The typical masses of impurities measured after both steps were less than 1 μg for Cr, Cu, and Ni while Fe and Zn was less than 2 μg. These data on overall recovery compare well with recent work by Rotsch et al. (2018) and Domnanich et al. (2017) where a 76.3% and 89.7% overall recovery was reported using branched DGA (N,N,N′,N′-tetrakis-2-ethylhexyl-diglycolamide) cation-exchange resin [20, 36]. Further, the mass of Zn and Fe measured in the purified 47Sc fraction was reduced by 60% and 45%, respectively, compared to the mass reported by Rotsch et al. (2018) [20].

As a proof of concept, the purified 47Sc was used to radiolabel DOTATOC, a somatostatin analog that when radiolabeled can be used for diagnosis and therapy of neuroendocrine tumors that overexpress SSTR2. This small peptide was selected due to its well-characterized affinity for trivalent radiometals [37]. A high radiochemical yield of 99.9% was achieved for the radiosynthesis of [47Sc]Sc-DOTATOC, which was subsequently used in an in vitro cell uptake assay in SSTR2-expressing AR42J cells. The maximum uptake was achieved by 2 h, and co-incubation of the radiolabeled compound with Octreotide lead to a 70% reduction in uptake at 2 h, indicating receptor-mediated uptake. In previous work, [43,44Sc]Sc-DOTATOC has been synthesized and evaluated for SSTR2-binding; however, the work performed in this study illustrates the feasibility of performing initial radiosynthetic and pre-clinical screening studies using the moderate 47Sc yields obtained from a CLINAC [13, 29, 38, 39].

Conclusion

This work demonstrated the photonuclear production of 47Sc using a modified Varian CLINAC, tungsten radiator, and targets composed of natTi foil. These results show that CLINACs no longer in clinical use may be used for the production of limited quantities of medically relevant radionuclides for small-scale experiments. Moreover, the methods shown in this work when applied to increased 47Sc production yields would likely result in higher molar activities. Based on this work, future photonuclear production of 47Sc using enriched 48Ti targets and high-intensity eLINACs may be a feasible route to developing this promising theranostic radionuclide; however, the limited cross-section data on the 48Ti(γ,p)47Sc reaction must be improved in order to optimize radionuclidic purity and 47Sc yield.

Notes

Acknowledgements

Not applicable.

Funding

This research was partially funded by the Indiana University Vice Provost for Research through the Faculty Research Support Program.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

Experiments were carried out by CSL, LLR, SJF, SLQ, MRS and SEL. M.R.S. operated the eLINAC and irradiated target foils. Data analyses was carried out by CSL, LLR, MRS, and SEL. CSL wrote the main manuscript text and prepared Figs. 1, 2, 3, 4 and 5, Table 1, and Additional file 1. All authors reviewed and edited the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary material

13550_2019_515_MOESM1_ESM.pdf (56 kb)
Additional file 1: Figure S1. (A) HPLC of DOTATOC (blue, tR = 8.8 min) and radio-HPLC of 47Sc (red, tR = 1.9 min). (B) HPLC of DOTATOC (blue, tR = 8.8 min) and radio-HPLC of [47Sc]Sc-DOTATOC (red, tR = 8.5 min). (C) Radio-TLC of 47Sc (Rf = 0) and (D) [47Sc]Sc-DOTATOC (Rf = 0.8) in 0.25 M ammonium acetate developed in a 1:1 mixture of 1.0 M ammonium acetate and methanol. (PDF 55 kb)

References

  1. 1.
    Srivastava SC, Mausner LF. Therapeutic radionuclides: production, physical characteristics, and applications. In: Baum RP, editor. Therapeutic nuclear medicine. Berlin, Heidelberg: Springer Berlin Heidelberg; 2014. p. 11–50.Google Scholar
  2. 2.
    Jeong H-J, Lee BC, Ahn B-C, Kang KW. Development of drugs and Technology for Radiation Theragnosis. Nucl Eng Technol. 2016;48(3):597–607.CrossRefGoogle Scholar
  3. 3.
    Baum RP, Kulkarni HR. THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy - the Bad Berka experience. Theranostics. 2012;2(5):437–47.CrossRefGoogle Scholar
  4. 4.
    Nicolas GP, Mansi R, McDougall L, Kaufmann J, Bouterfa H, Wild D, et al. Biodistribution, pharmacokinetics, and dosimetry of (177) Lu-, (90) Y-, and (111) in-labeled somatostatin receptor antagonist OPS201 in comparison to the agonist (177) Lu-DOTATATE: the mass effect. J Nuclear Med, Society of Nuclear Medicine. 2017;58(9):1435–41.CrossRefGoogle Scholar
  5. 5.
    Gudkov SV, Shilyagina NY, Vodeneev VA, Zvyagin AV. Targeted radionuclide therapy of human tumors. Int J Mol Sci. 2016;17(1):33.CrossRefGoogle Scholar
  6. 6.
    Rösch F, Herzog H, Qaim MS. The beginning and development of the theranostic approach in nuclear medicine, as exemplified by the radionuclide pair 86Y and 90Y. Pharmaceuticals. 2017;10(2):56.Google Scholar
  7. 7.
    Srivastava SC. Paving the way to personalized medicine: production of some promising Theragnostic radionuclides at Brookhaven National Laboratory. Semin Nucl Med. 2012;42(3):151–63.CrossRefGoogle Scholar
  8. 8.
    Leveque DW, Sandra JF. Pharmacokinetics of therapeutic monoclonal antibodies used in oncology. Anticancer Res. 2005;25(3C):2327–43.PubMedGoogle Scholar
  9. 9.
    Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122–8.CrossRefGoogle Scholar
  10. 10.
    Mamtimin M, Harmon F, Starovoitova VN. Sc-47 production from titanium targets using electron linacs. Appl Radiat Isot. 2015;102:1–4.CrossRefGoogle Scholar
  11. 11.
    Frank R. Scandium-44: benefits of a long-lived PET radionuclide available from the 44Ti/44Sc generator system. Curr Radiopharm. 2012;5(3):187–201.CrossRefGoogle Scholar
  12. 12.
    Bartoś B, Majkowska A, Krajewski S, Bilewicz A. New separation method of no-carrier-added 47Sc from titanium targets. Radiochimica Acta International Journal For Chemical Aspects Of Nuclear Science and Technology2012. p. 457.Google Scholar
  13. 13.
    Müller C, Bunka M, Haller S, Köster U, Groehn V, Bernhardt P, et al. Promising prospects for 44Sc−/47Sc-based theragnostics: application of 47Sc for radionuclide tumor therapy in mice. J Nucl Med. 2014;55(10):1658–64.CrossRefGoogle Scholar
  14. 14.
    Misiak R, Walczak R, Wąs B, Bartyzel M, Mietelski JW, Bilewicz A. 47Sc production development by cyclotron irradiation of 48Ca. J Radioanal Nucl Chem. 2017;313(2):429–34.CrossRefGoogle Scholar
  15. 15.
    Gadioli E, Gadioli Erba E, Hogan JJ, Burns KI. Emission of alpha particles in the interaction of 10–85 MeV protons with48,50Ti. Zeitschrift für Physik A Atoms Nuclei. 1981;301(4):289–300.CrossRefGoogle Scholar
  16. 16.
    DeLorme K, Engle J, Kowash B, Nortier F, Birnbaum E, McHale S, et al. Production potential of Sc-47 using spallation neutrons at the Los Alamos isotope production facility. J Nucl Med Meeting Abstracts. 2014;55(1_MeetingAbstracts):1468.Google Scholar
  17. 17.
    Habs D, Köster U. Production of medical radioisotopes with high specific activity in photonuclear reactions with γ-beams of high intensity and large brilliance. Applied Physics B. 2011;103(2):501–19.CrossRefGoogle Scholar
  18. 18.
    Belyshev SS, Dzhilavyan LZ, Ishkhanov BS, Kapitonov IM, Kuznetsov AA, Orlin VN, et al. Photonuclear reactions on titanium isotopes. Phys At Nucl. 2015;78(2):220–9.CrossRefGoogle Scholar
  19. 19.
    Starovoitova VN, Cole PL, Grimm TL. Accelerator-based photoproduction of promising beta-emitters 67Cu and 47Sc. J Radioanal Nucl Chem. 2015;305(1):127–32.CrossRefGoogle Scholar
  20. 20.
    Rotsch DA, Brown MA, Nolen JA, Brossard T, Henning WF, Chemerisov SD, et al. Electron linear accelerator production and purification of scandium-47 from titanium dioxide targets. Appl Radiat Isot. 2018;131:77–82.CrossRefGoogle Scholar
  21. 21.
    Sherwood TR, Turchinetz WE. Some photo-disintegration reactions in the titanium isotopes. Nucl Phys. 1962;29:292–9.CrossRefGoogle Scholar
  22. 22.
    Bodnar EN, Dikiy MP, Medvedeva EP. Photonuclear production and antitumor effect of radioactive cisplatin (195mPt). J Radioanal Nucl Chem. 2015;305(1):133–8.CrossRefGoogle Scholar
  23. 23.
    Smith NA, Bowers DL, Ehst DA. The production, separation, and use of 67Cu for radioimmunotherapy: a review. Appl Radiat Isot. 2012;70(10):2377–83.CrossRefGoogle Scholar
  24. 24.
    Grimm TL, Boulware CH, Hollister JL, Jecks RW, Mamtimin M, Starovoitova V. Commercial superconducting electron linac for radioisotope production. ; Niowave, Inc., Lansing, MI (United States); 2015. Report No.: 13–0019--FTR-0001; Other: 13–0019 United States  https://doi.org/10.2172/1209691 Other: 13-0019 CHO English.
  25. 25.
    Queern SL, Cardman R, Loveless CS, Shepherd MR, Lapi SE. Production of 15O for Medical Applications via the 16O(gamma,n)15O Reaction. J Nucl Med. 2019;60:424-8.Google Scholar
  26. 26.
    Kolsky KL, Joshi V, Mausner LF, Srivastava SC. Radiochemical purification of no-carrier-added scandium-47 for radioimmunotherapy. Appl Radiat Isot. 1998;49(12):1541–9.CrossRefGoogle Scholar
  27. 27.
    Gray PW, Ahmad A. Linear classes of Ge (li) detector efficiency functions. Nucl Inst Methods Phys Res A. 1985;237(3):577–89.CrossRefGoogle Scholar
  28. 28.
    Wooten AL, Lewis BC, Lapi SE. Cross-sections for (p,x) reactions on natural chromium for the production of (52,52m,54) Mn radioisotopes. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, vol. 96; 2015. p. 154–61.Google Scholar
  29. 29.
    Pruszyński M, Majkowska-Pilip A, Loktionova NS, Eppard E, Roesch F. Radiolabeling of DOTATOC with the long-lived positron emitter 44Sc. Appl Radiat Isot. 2012;70(6):974–9.CrossRefGoogle Scholar
  30. 30.
    Schwarzenbach G, Muehlebach J, Mueller K. Peroxo complexes of titanium. Inorg Chem. 1970;9(11):2381–90.CrossRefGoogle Scholar
  31. 31.
    Anthony L, Freda PU. From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin. 2009;25(12):2989–99.CrossRefGoogle Scholar
  32. 32.
    Patel YC, Srikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology. 1994;135(6):2814–7.CrossRefGoogle Scholar
  33. 33.
    Luu A. Ti isotopes budgetary pricing. San Francisco: Isoflex; 2018. p. 1.Google Scholar
  34. 34.
    Strelow FWE. Distribution coefficients and ion exchange behavior of 46 elements with a macroreticular cation exchange resin in hydrochloric acid 1984.Google Scholar
  35. 35.
    Oehlke E, Le V, Lengkeek N, Pellegrini P, Jackson T, Greguric I, et al. Influence of metal ions on the Ga-68-labeling of DOTATATE; 2013. p. 232–8.Google Scholar
  36. 36.
    Domnanich KA, Eichler R, Müller C, Jordi S, Yakusheva V, Braccini S, et al. Production and separation of 43Sc for radiopharmaceutical purposes. EJNMMI Radiopharmacy and Chem. 2017;2(1):14.CrossRefGoogle Scholar
  37. 37.
    Liu S. The role of coordination chemistry in the development of target-specific radiopharmaceuticals. Chem Soc Rev. 2004;33(7):445–61.CrossRefGoogle Scholar
  38. 38.
    Hernandez R, Valdovinos HF, Yang Y, Chakravarty R, Hong H, Barnhart TE, et al. 44Sc: an attractive isotope for peptide-based PET imaging. Mol Pharm. 2014;11(8):2954–61.CrossRefGoogle Scholar
  39. 39.
    Walczak R, Krajewski S, Szkliniarz K, Sitarz M, Abbas K, Choiński J, et al. Cyclotron production of (43) Sc for PET imaging. EJNMMI Physics. 2015;2:33.CrossRefGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Department of RadiologyUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Department of ChemistryWashington University in St. LouisSt. LouisUSA
  3. 3.Department of ChemistryUniversity of Alabama at BirminghamBirminghamUSA
  4. 4.Department of PhysicsIndiana UniversityBloomingtonUSA

Personalised recommendations